What Do Recent Reports on Tysabri and PML Show?
From General Health Information to Specific Risk Awareness
If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established PML as a rare but serious adverse event linked to this medication. This page reviews the latest research findings and risk factors to help you stay informed.
Understanding Tysabri and Its Link to PML
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning further notes that risk factors for PML include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to be enrolled, read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable but typically includes progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. In FAERS adverse-event reports for Tysabri, the most frequently reported events include fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically confirm PML, they reflect the types of neurological symptoms that could be consistent with PML or other complications. The label warns that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Mechanism of PML Development and Risk Factors
The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents lymphocytes from crossing the blood-brain barrier, thereby reducing immune surveillance in the central nervous system. This immunosuppressive effect allows the JC virus, which is latent in many individuals, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The presence of anti-JCV antibodies is a key risk factor because it indicates prior exposure to the virus. Longer treatment duration, especially beyond two years, increases cumulative immunosuppression and the likelihood of viral reactivation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients in Arizona who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability or personal injury claim. In Arizona, the statute of limitations for personal injury actions is generally two years from the date the injury is discovered or reasonably should have been discovered. For medical malpractice claims, the statute is also two years, but with a maximum of six years from the date of the negligent act. Given that PML symptoms may develop gradually and diagnosis can be delayed, the discovery rule is critical. The timeline between Tysabri exposure and documented harm can vary from months to several years, as noted in the label for herpes infections, where onset ranged from a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For PML, the risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Legal Implications and Statute of Limitations in Arizona
Adequacy of warnings is a central issue in any legal claim. The boxed warning clearly states that Tysabri increases the risk of PML and lists known risk factors. However, questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, the need for regular monitoring, and the importance of early symptom recognition. The TOUCH program is designed to ensure that patients are informed and that prescribing is controlled, but failures in implementation or communication could form the basis of a claim. Affected patients should consult with an attorney experienced in pharmaceutical litigation to evaluate whether the statute of limitations has been met and whether the warnings provided were sufficient under Arizona law.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in Arizona?
In Arizona, the statute of limitations for personal injury actions is generally two years from the date the injury is discovered or reasonably should have been discovered. For medical malpractice claims, it is also two years, with a maximum of six years from the negligent act. Given the delayed onset of PML, the discovery rule is critical. Consult an attorney promptly.
What are the risk factors for developing PML from Tysabri?
Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. The boxed warning details these factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.